iScience · 2024 · 13 citations · 42 references
Life SciencesImmunologyOncologyImmunotherapyMetabolomicsProteomicsCancer BiomarkersCancer ImmunotherapyImmune-related Adverse EventsImmuno-oncology BiomarkersProteomic BiomarkersProteomic ProfilingImmune Checkpoint Inhibitor BiomarkersImmune-related Adverse Event BiomarkersImmunotherapy BiomarkersLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMetabolomic BiomarkersPredictive Biomarker DiscoveryPredictive Biomarkers
<h2>Summary</h2> The clinical success of immune checkpoint inhibitors is compromised by the fact of immune-related adverse events (irAEs), especially for older patients. To identify predictive biomarkers for older patients with irAEs, we used multiplex immunoassay and flow cytometry and liquid chromatography-tandem mass spectrometry to test immune factors and plasma protein and metabolites levels in non-small cell lung cancer (NSCLC) patients. The results showed that older patients with irAEs displayed lower CD28, CD4<sup>+</sup> T cell, and B cell and higher interleukin (IL)-10 and CCL2 levels at baseline. Besides, lower aldolase, fructose-bisphosphate B (ALDOB), higher ST6GAL1, and lower lactate/pyruvate ratio at baseline were found in older patients with irAEs. Based on metabolomic markers, predictive models were developed to distinguish patients with grade 2–4 irAEs from grade 0–1 (Area under curve, AUC = 0.831) and to distinguish patients with grade 3–4 irAEs from grade 2 (AUC = 1). Our results confirmed the predictive value of plasma metabolites for irAEs in older patients with NSCLC.
42
Cancer treatment and survivorship statistics, 2022
Kimberly D. Miller, Letícia Nogueira, Theresa P. Devasia et al. · CA A Cancer Journal for Clinicians · 2022 · 3.7K citations · Full text
Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text
Medicine, Oncology, Pharmacology +15
iProX: an integrated proteome resource
Jie Ma, Tao Chen, Songfeng Wu et al. · Nucleic Acids Research · 2018 · 2K citations · Full text
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2019 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +17
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
McLane J. Watson, Paolo Vignali, Steven J. Mullett et al. · Nature · 2021 · 1.2K citations · Full text
Life Sciences, Immunology, Oncology +16